A Phase 1, Single-Center, Dose-Escalation Study to Determine the Safety and Pharmacokinetics of a Single Oral Dose of PF614 in Healthy Subjects Compared to OxyContin®
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Oxycodone (Primary)
- Indications Pain
- Focus Adverse reactions
- Acronyms SAD
- Sponsors Ensysce Biosciences
- 02 Dec 2017 Cohort 7 has been added into the study and 16 subjects were enrolled for the cohort.
- 02 Dec 2017 Planned number of patients changed from 48 to 64.
- 02 Dec 2017 Planned End Date changed from 1 Jun 2017 to 5 Jan 2018.